Pay in 4 interest-free payments of $36.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
including AKT
The increased hepatic α-SMA expression is markedly decreased in SOD1mu mice treated with GKT137831
1 S cells) treatment induces apoptosis
InChi: InChI=1S/C52H59NO18/c1-26-33(68-47(63)39(58)37(29-16-10-7-11-17-29)53-45(61)30-18-12-8-13-19-30)23-52(64)44(70-46(62)31-20-14-9-15-21-31)42-50(6
31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-14
OSU-T315 - CAS# 2070015-22-2 Size:10mg solid including AKTOSU T315 (ILK IN 1) is a small Integrin linked kinase (ILK) inhibitor with an IC50 of 0. 6 M, inhibiting PI3K AKT signaling by dephosphorylation of AKT Ser473 and other ILK targets (GSK 3 and myosin light chain). OSU T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase dependent apoptosis in an ILK independent manner[2]. OSU T315 causes cell death through apoptosis and autophagy. Product information CAS